Contrast Agents and Radiopharmaceuticals | Market Insights | Europe | 2019
Despite stringent reimbursement regulations and the ongoing safety controversy surrounding GBCAs, the European contrast agent and radiopharmaceutical market will exhibit slight growth through 2027, propelled by ASP hikes in the radiopharmaceutical space and the increasing demand for diagnostic imaging procedures for Europe’s aging population.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals in Europe across a 10-year period.